Saturday 17 October 2026
Export ANNX’s income statement to Excel — free account
Annexon, Inc.
ANNX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.41
0.19
−5.28%
Follow ANNX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.68 | 13.74 | 9.21 | 33.33 | 11.39 | 11.10 | 14.72 | 10.37 | 5.68 |
Net Debt/EBITDA |
(2.28) | 2.37 | 1.37 | 5.59 | 1.89 | 1.69 | 1.83 | 2.05 | 1.11 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.06) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.02 | 0.93 | 0.74 | 0.75 | 0.81 | 0.82 | 0.90 | 0.85 | 0.89 |
Capex/Depreciation |
0.00 | (0.03) | (0.54) | (0.70) | (0.77) | (3.10) | (0.09) | (0.01) | (0.06) |
| 34.04% | 33.47% | 46.49% | (57.69%) | (45.24%) | (61.30%) | (55.73%) | (50.84%) | (82.63%) | |
| (67.16%) | (76.76%) | (78.08%) | (34.66%) | (40.54%) | (49.62%) | (46.07%) | (42.67%) | (66.45%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(392.13%) | (41.32%) | (89.83%) | (20.37%) | (53.46%) | (58.52%) | (51.49%) | (46.28%) | (99.22%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.50) | (42.73) | (66.03) | (3.16) | (2.81) | (2.25) | (1.60) | (0.86) | (1.20) |
Cash per Share |
0.08 | 109.70 | 101.34 | 20.71 | 6.33 | 4.44 | 3.43 | 2.27 | 1.54 |
Shareholders Equity per Share |
(1.21) | (159.43) | (231.73) | 20.30 | 6.05 | 4.23 | 3.31 | 2.13 | 1.36 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.21) | (159.43) | (231.73) | 20.30 | 6.05 | 4.23 | 3.31 | 2.13 | 1.36 |
Free Cash Flow |
(19.26) | (17.21) | (28.62) | (53.55) | (107.76) | (122.83) | (121.33) | (118.02) | (186.49) |
Working Capital |
1.98 | 42.38 | 40.48 | 343.39 | 225.95 | 225.74 | 245.93 | 285.95 | 199.56 |
Capital Expenditures |
(0.57) | (0.02) | (0.27) | (0.46) | (1.65) | (6.53) | (0.19) | (0.01) | (0.14) |
Net Current Asset Value |
(49.14) | (66.64) | (104.95) | 342.34 | 192.56 | 194.20 | 216.74 | 259.50 | 176.27 |
| Other line items | |||||||||
Quick Ratio |
1.22 | 13.28 | 8.91 | 33.06 | 11.16 | 10.85 | 14.49 | 10.23 | 5.59 |
Depreciation/Fixed assets |
0.10 | 0.21 | 0.23 | 0.34 | 0.12 | 0.13 | 0.15 | 0.17 | 0.20 |
Cash ROIC |
(336.36%) | 85.92% | 50.64% | (7.70%) | (22.71%) | (25.92%) | (23.78%) | (19.50%) | (41.44%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
2,052.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.50) | (42.69) | (65.42) | (3.13) | (2.77) | (2.13) | (1.60) | (0.86) | (1.20) |
Capex per Share |
0.00 | (0.04) | (0.62) | (0.03) | (0.04) | (0.12) | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.40 | 0.40 | 0.15 | 0.04 | — | — | — | — | — |
Average Payables |
1.40 | 1.40 | 1.82 | 3.05 | 7.44 | 9.28 | 6.45 | 7.96 | 12.68 |
Average Assets |
27.99 | 24.07 | 49.02 | 202.92 | 321.49 | 286.07 | 291.39 | 323.87 | 313.82 |
Average Common Equity |
(55.21) | (55.21) | (82.33) | 121.91 | 288.09 | 231.55 | 240.88 | 271.83 | 252.38 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates